FDA Approves Akebia's Vafseo for Anemia in Chronic Kidney Disease
The FDA has approved Akebia Therapeutics' Vafseo (vadadustat) tablets for anemia due to chronic kidney disease in adults on dialysis for at least three months. Vafseo, a once-daily oral medication, activates the body's response to low oxygen levels to stimulate the production of erythropoietin, managing anemia. With approval in 37 countries and an estimated peak sales of $954 million in 2031, Akebia plans to launch Vafseo in the U.S. later this year, aiming to establish it as a new standard of care for adult dialysis patients.